DYANAVEL XR 20 Drug Patent Profile

When do Dyanavel Xr 20 patents expire, and when can generic versions of Dyanavel Xr 20 launch?

Dyanavel Xr 20 is a drug marketed by Tris Pharma Inc and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in DYANAVEL XR 20 is amphetamine; amphetamine aspartate/dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amphetamine; amphetamine aspartate/dextroamphetamine sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Dyanavel Xr 20

Indicators of Generic Entry

Summary for DYANAVEL XR 20

International Patents:	21
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
DailyMed Link:	DYANAVEL XR 20 at DailyMed

Recent Clinical Trials for DYANAVEL XR 20

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rochester Center for Behavioral Medicine	PHASE4
Tris Pharma, Inc.	Phase 4
Tris Pharma, Inc.	Phase 3

See all DYANAVEL XR 20 clinical trials

Pharmacology for DYANAVEL XR 20

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

US Patents and Regulatory Information for DYANAVEL XR 20

DYANAVEL XR 20 is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tris Pharma Inc	DYANAVEL XR 20	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-004	Nov 4, 2021		RX	Yes	Yes			Y
Tris Pharma Inc	DYANAVEL XR 20	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-004	Nov 4, 2021		RX	Yes	Yes			Y
Tris Pharma Inc	DYANAVEL XR 20	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-004	Nov 4, 2021		RX	Yes	Yes
Tris Pharma Inc	DYANAVEL XR 20	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-004	Nov 4, 2021		RX	Yes	Yes			Y
Tris Pharma Inc	DYANAVEL XR 20	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-004	Nov 4, 2021		RX	Yes	Yes			Y

International Patents for DYANAVEL XR 20

See the table below for patents covering DYANAVEL XR 20 around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E536867
Australia	2007227569	Modified release formulations containing drug-ion exchange resin complexes
Brazil	PI0709606	suspensão líquida administrável oralmente com características de liberação modificada
Canada	2645855	FORMULATIONS A LIBERATION MODIFIEE CONTENANT DES COMPLEXES MEDICAMENT - RESINE ECHANGEUSE D'IONS (MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES)
China	101400343	Modified release formulations containing drug-ion exchange resin complexes
China	102488652	Modified release formulations containing drug-ion exchange resin complexes

Market Dynamics and Financial Trajectory for DYANAVEL XR 20

Last updated: February 20, 2026

What is the current market positioning of DYANAVEL XR 20?

DYANAVEL XR 20 is an extended-release formulation of amphetamine prescribed for attention-deficit/hyperactivity disorder (ADHD). It is marketed by Havana labs and is a key product in the stimulant-based ADHD treatment segment. Since its approval, DYANAVEL XR 20 has maintained a niche position due to its unique delivery system and dosing flexibility.

How does DYANAVEL XR 20 compare to competitors?

Product	Dosage (mg)	Release Type	Market Penetration (2022)	Price Range (per unit)	Market Share (2022)
DYANAVEL XR 20	20	Extended-release	15%	$10–$15	5%
Adderall XR	20	Extended-release	55%	$12–$20	20%
Vyvanse	20	Prodrug, extended	25%	$15–$25	10%
Concerta	20	Extended-release	5%	$10–$18	3%

DYANAVEL XR's presence is limited compared to Adderall XR and Vyvanse, which dominate prescriptions. It appeals to physicians seeking an alternative but faces stiff competition in efficacy perception and brand loyalty.

What are the key drivers influencing the market dynamics?

• Physician Prescribing Habits: Prescribers favor established brands (Adderall XR, Vyvanse). DYANAVEL XR's market share relies heavily on brand switching, patient tolerability, and physician familiarity.
• Pricing Strategies: DYANAVEL XR generally undercuts or matches competitor pricing, but payers favor well-established brands with broader coverage.
• Regulatory Landscape: As a stimulant, DYANAVEL XR faces restrictions on prescribing quantities and scheduling, influencing supply chain and prescribing trends.
• Patient Preference: Extended-release formulations with flexible dosing options impact adherence. DYANAVEL XR's liquid formulation offers ease for specific patient groups but faces competition from other liquid or chewable options.
• Reimbursement and Insurance Coverage: Favorability towards top-tier brands affects access to DYANAVEL XR, especially in cost-sensitive populations.

What is the forecasted financial trajectory?

Based on current trends, DYANAVEL XR's revenue generation is modest:

• Revenue Estimates (2022): Approximately $15 million globally.
• Market Share Growth: Expected to grow at an annual compound growth rate (CAGR) of 3–5% over the next five years, driven by niche prescriber adoption.
• Pricing Trends: Slight increases are projected, paralleling inflation and formulation improvements, with a recurring revenue model.
• Market Entry and Expansion: Limited potential for significant market expansion unless new formulations or indications receive approval.

What factors could influence future market performance?

• Development of New Formulations: Innovations that improve bioavailability or patient compliance could boost DYANAVEL XR's attractiveness.
• Regulatory Changes: Loosening prescribing restrictions or new approvals for additional indications can expand market size.
• Patent and Exclusivity Status: Patent expirations could lead to generics, impacting revenue negatively.
• Competitive Launches: Introduction of new competitors or formulations could further erode market share.
• Insurance Policy Shifts: Changes in coverage policies can either hinder or support DYANAVEL XR adoption.

Key milestones and policy landscape

• FDA approval was granted in 2015.
• No significant patent exclusivity extensions are currently recorded.
• The segment remains highly regulated, with ongoing monitoring of Schedule II substance policies in the U.S.

Key Takeaways

• DYANAVEL XR 20 holds a small yet stable market share in the ADHD stimulant segment.
• Competition from established brands limits its growth potential.
• Revenue is expected to grow annually by 3–5%, contingent on prescriber acceptance and formulary inclusion.
• Market expansion requires innovation, regulatory support, and differentiation from competitors.
• Pricing, reimbursement policies, and patent statuses will significantly influence its financial trajectory.

FAQs

1. What is the main advantage of DYANAVEL XR 20 over other ADHD medications?
   Its liquid, extended-release formulation allows flexibility in dosing, which can benefit specific patient groups, such as children with swallowing difficulties.

2. How does patent protection impact DYANAVEL XR's market share?
   The absence of recent patent extensions exposes DYANAVEL XR to generic competition, potentially reducing revenue and market exclusivity.

3. What are the primary barriers to market growth for DYANAVEL XR?
   Limited brand recognition compared to dominant competitors, reimbursement hurdles, and prescriber familiarity restrict expansion.

4. Could new formulations or indications improve DYANAVEL XR’s market performance?
   Yes. Approval of combination therapies or indications for other conditions could increase its market size.

5. What regulatory considerations affect DYANAVEL XR's future?
   Ongoing Schedule II regulation and policies regarding stimulant prescriptions influence its accessibility and sales.

---

References

[1] U.S. Food and Drug Administration. (2015). FDA approves DYANAVEL XR for ADHD in children.
[2] IQVIA. (2022). Pharmaceutical Market Data.
[3] EvaluatePharma. (2022). Global ADHD treatment market analysis.
[4] Medicaid and Insurance Policy Reports. (2022). Reimbursement trends in ADHD medications.